Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Convertible Debt: 2019-2023

Historic Convertible Debt for Ocular Therapeutix (OCUL) over the last 5 years, with Dec 2023 value amounting to $9.1 million.

  • Ocular Therapeutix's Convertible Debt fell 68.21% to $9.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $9.1 million, marking a year-over-year decrease of 68.21%. This contributed to the annual value of $9.1 million for FY2023, which is 68.21% down from last year.
  • Per Ocular Therapeutix's latest filing, its Convertible Debt stood at $9.1 million for FY2023, which was down 68.21% from $28.7 million recorded in FY2022.
  • In the past 5 years, Ocular Therapeutix's Convertible Debt ranged from a high of $28.7 million in FY2022 and a low of $9.1 million during FY2023.
  • For the 3-year period, Ocular Therapeutix's Convertible Debt averaged around $21.4 million, with its median value being $26.4 million (2021).
  • In the last 5 years, Ocular Therapeutix's Convertible Debt grew by 8.75% in 2021 and then slumped by 68.21% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Convertible Debt (Yearly) stood at $24.3 million in 2019, then grew by 0.01% to $24.3 million in 2020, then increased by 8.75% to $26.4 million in 2021, then rose by 8.75% to $28.7 million in 2022, then slumped by 68.21% to $9.1 million in 2023.